Clinical Trials

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05063552 2026-03-18

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

430 enrolled

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07063745 2026-03-17

MountainTAP-29

590 enrolled

Lung Neoplasms

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

613 enrolled

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

116 enrolled

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

470 enrolled

Urinary Bladder Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05050162 2026-03-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT07100080 2026-03-03

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

596 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06236438 2026-02-23

LIVIGNO-4

840 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Urinary Bladder Neoplasms

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

950 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer